# A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate

Source: https://onco.cc/trials/nct01517802/  
OnCo record `nct01517802` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Abiraterone acetate and Prednisone in Prostate cancer, run by Janssen Research & Development, LLC, completed.

## Summary

A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate is a phase 3 interventional study registered as NCT01517802 by Janssen Research & Development, LLC, with 32 participants recorded, started 2012-03-28 and reaching its primary completion in 2021-04-22. Interventions recorded: Abiraterone acetate, Prednisone. Conditions recorded: Metastatic Castration-resistant Prostate Cancer, Metastatic Breast Cancer.

Linked to the idea "Prescribe a quarter dose of abiraterone with breakfast" because the registry names Abiraterone acetate and Prednisone among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT01517802
- Phase: 3
- Setting: A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 32

## Sources

- ClinicalTrials.gov NCT01517802: https://clinicaltrials.gov/study/NCT01517802

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Abiraterone acetate](https://onco.cc/drugs/abiraterone/), [Prednisone](https://onco.cc/drugs/prednisone/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)
- ideas: [Prescribe a quarter dose of abiraterone with breakfast](https://onco.cc/ideas/idea-cost-low-dose-abiraterone-food/)

---
JSON: https://onco.cc/api/v1/entities/nct01517802.json